Understand the source comparison
Best Peptides for Scar Healing: Clinical Evidence Comparison
The table below compares the three peptides with the strongest published evidence for scar healing based on mechanism, clinical trial data, application method, and observed outcomes. BPC-157 VEGF upregulation, NO pathway activation, collagen type I synthesis 6
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares the three peptides with the strongest published evidence for scar healing based on mechanism, clinical trial data, application method, and observed outcomes.
- BPC-157
- VEGF upregulation, NO pathway activation, collagen type I synthesis
- 60–80% increase in angiogenesis; 40–60% reduction in hypertrophic scar formation vs controls (J Physiol Paris, rodent models)
- Subcutaneous injection 1–2 cm from wound edge, 200–500 mcg daily
- Localized. 10–15× higher concentration near injection site vs systemic
- Strongest evidence for acute wound healing and surgical scar prevention when initiated within 72 hours post-injury
- GHK-Cu
- MMP-2/9 activation, decorin binding, collagen type I:III ratio normalization
- Improved collagen I:III ratio from 1.2:1 to 3.8:1 in fibroblast cultures (Biomed Pharmacother 2015)
- Topical application in DMSO or liposomal carrier, 1–3 mg twice daily
- Moderate. 12–18% transdermal bioavailability with penetration enhancers
- Best for post-surgical scars and acne scars when applied during early remodeling phase (weeks 2–12)
- TB-500
- Actin sequestration, keratinocyte/fibroblast migration, laminin-5 upregulation
- 30–42% reduction in wound closure time in full-thickness injuries (Ann NY Acad Sci)
- Subcutaneous injection, systemic distribution, 2–5 mg twice weekly
- Systemic. Distributes throughout body, not site-specific
- Most effective for large surface area injuries (burns, abrasions) where systemic promotion of cell migration accelerates overall healing